Bioclinica buys Clinverse citing pharma demand for trial payment efficiency

By Gareth Macdonald

- Last updated on GMT

Related tags Pharmacology

Bioclinica HQ
Bioclinica HQ
Bioclinica has bought payment tech firm Clinverse continuing its acquisition-based growth strategy.

Buying Research Triangle Park (RTP) Durham, North Carolina-based Clinverse – financial terms of which were not provided – has added a portfolio of automated clinical trial payment services to Bioclinica’s eHealthSolutions business.

The payment firm’s previous investors include Hatteras Venture Partners of Durham and New Jersey-based Edison Partners, which led by a $9.1m (€6.9m) round in August 2014​.

Clinverse’s approach is to automatically track tax and exchange rate changes and automate payments to clinical trial sites and study participants.

The firm partnered with OmniComm Systems in 2013​ to combine its Clinpay automated payment tool with the latter’s electronic data capture (EDC) offering.

Bioclinica has not said whether this partnership will be maintained post-acquisition.  

The takeover continues the strategy Bioclinica enacted recent years.

In 2014, Bioclinica bought Blueprint Clinical​, a tech firm whose software helps drugmakers develop risk-based monitoring plans. 

A year later it acquired retention services firm MediciGroup​ and in September it bought pharmacovigilance and regulatory tech firm Synowledge​. 

Automated payment

In 2013, the US Government introduced the Sunshine Act​ in a bid to make financial interactions during the drug development process more transparent.

Since August of that year, drug companies and their contractors have been required to record all details of all the financial interactions they make, including payments to study investigators.

The need to collect and store this information in an efficient manner fuelled the growth of tech companies with Clinverse and peers like Greenphire and CFS competing for control of the increasingly lucrative market.

Bioclinica’s acquisition of Clinverse leaves Greephire as the last of these three firms to be independent. CFS was bought by DrugDev in October 2013​.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more